BSE · 540788
Aspira Pathlab & Diagnostics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹6 Cr with net profit ₹-0 Cr — a -0.65% net margin, versus -10.58% the period before.
Shareholding
As of 2026-09-30
- Promoter46.65%
- Public53.35%
1,603 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.06× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #40 of 87 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,21,441 Cr | 53.63 | 11.45 | 21.14% | 8.12% |
| Max Healthcare Institute Ltd. | ₹90,909 Cr | 64.02 | 8.02 | 12.18% | 15.1% |
| Manipal Health Enterpri Limited | ₹85,065 Cr | 90.7 | 5.18 | 10.59% | 7.81% |
| Aster DM Quality Care Ltd. | ₹62,142 Cr | 160.2 | 14.77 | 8.48% | 6.54% |
| Fortis Healthcare Ltd. | ₹57,898 Cr | 54.27 | 5.53 | 9.91% | 10.48% |
| Narayana Hrudayalaya Ltd. | ₹38,890 Cr | 42.98 | 7.77 | 17.17% | 8.36% |
| Global Health Limited | ₹37,309 Cr | 57.62 | 8.63 | 14.3% | 12.24% |
| Dr. Lal Path Labs Ltd. | ₹33,066 Cr | 54.59 | 12.03 | 21.32% | 19.29% |
| Krishna Institute of Medical Sciences Ltd. | ₹30,366 Cr | 149.38 | 7.72 | 5.4% | 4.62% |
| Dr. Agarwal's Health Care Limited | ₹16,371 Cr | 111.04 | 7.32 | 8.04% | 7.61% |
| Aspira Pathlab & Diagnostics Ltd.(this company) | ₹138 Cr | 57.34 | 19 | 16.62% | 10.61% |
AI analysis
AI-generated · google/gemini-2.5-flashAspira Pathlab & Diagnostics Ltd. is listed with a market capitalization of Rs 96 Cr. The company reported revenue of Rs 22.39 Cr and a profit margin of 10.61%. Earnings per share (EPS) stood at Rs 2.33, with a return on equity (ROE) of 16.62% and return on capital employed (ROCE) of 13.17%.
Positives
- +Debt-to-equity ratio is low at 0.15.
- +Return on Equity (ROE) is 16.62%.
- +Return on Capital Employed (ROCE) is 13.17%.
Negatives
- −Promoter shareholding is low at 18.39% as of March 31, 2026.
- −The company reported a net loss of Rs -0.69 Cr in the quarter ending Mar 2026.
- −The company reported a net loss of Rs -1.56 Cr in the quarter ending Dec 2025.
- −Net profit has been negative for two consecutive quarters ending Dec 2025 and Mar 2026.
- −The company is currently under ESM (Enhanced Surveillance Measure).
Financial performance
Aspira Pathlab & Diagnostics Ltd. reported revenue of Rs 22.39 Cr. The company's profit margin stood at 10.61%. In the quarter ending Mar 2026, revenue was Rs 6.52 Cr with a net loss of Rs -0.69 Cr. In the preceding quarter ending Dec 2025, revenue was Rs 5.12 Cr with a net loss of Rs -1.56 Cr.
Profitability & returns
The company’s profitability metrics include an EPS of Rs 2.33. Return on equity (ROE) was 16.62%, and return on capital employed (ROCE) was 13.17%. The profit margin for the latest annual period was 10.61%.
Balance sheet
Aspira Pathlab & Diagnostics Ltd. has a debt-to-equity ratio of 0.15. The book value per share is Rs 7.03Cr.
Ownership & pledges
As of March 31, 2026, promoters held 18.39% of the company's shares. Public shareholding was 81.61%. There were no shares pledged by the promoters.
Regulatory & surveillance
The company is currently under ESM (Enhanced Surveillance Measure), specifically ESM 1, indicating enhanced monitoring by regulatory bodies.
Data as of — price: 2026-11-07 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Aspira Pathlab & Diagnostics Ltd.share price & fundamentals